ライフサイエンスコーパス: Hodgkin's disease

1 tt's lymphoma, nasopharyngeal carcinoma, and Hodgkin's disease.

2 effective in locally extensive and advanced Hodgkin's disease.

3 tutively activated in the malignant cells of Hodgkin's disease.

4 bulky mediastinal stage I/II or stage III/IV Hodgkin's disease.

5 nge, 2.65 to 29.88 years) after diagnosis of Hodgkin's disease.

6 The risk of breast cancer is increased after Hodgkin's disease.

7 men for children with relapsed or refractory Hodgkin's disease.

8 or effect on risk of second malignancy after Hodgkin's disease.

9 with heavily pretreated relapsed/refractory Hodgkin's disease.

10 tment with doxorubicin, and the diagnosis of Hodgkin's disease.

11 ervical-thoracic CT imaging of patients with Hodgkin's disease.

12 nd pairs in B-cell lymphoid malignancies and Hodgkin's disease.

13 eloid leukemia 17 months after treatment for Hodgkin's disease.

14 malignant neoplasms (SMNs) in children with Hodgkin's disease.

15 t biopsy samples from patients with relapsed Hodgkin's disease.

16 sion in EBV-induced lymphoproliferations and Hodgkin's disease.

17 apy for patients with relapsed or refractory Hodgkin's disease.

18 curring in untreated Reed-Sternberg cells of Hodgkin's disease.

19 ses of T- and null-cell NHL, and 18 cases of Hodgkin's disease.

20 athologically verified stage III or stage IV Hodgkin's disease.

21 31.6 years (mean, 13.1) after treatment for Hodgkin's disease.

22 have value in the treatment of EBV-positive Hodgkin's disease.

23 g cells and their variants from six cases of Hodgkin's disease.

24 year-old white girl diagnosed with stage IIa Hodgkin's disease.

25 ll lymphoma of T-cell lineage, and five with Hodgkin's disease.

26 eveloped AML 16 months from the diagnosis of Hodgkin's disease.

27 patients with nodular lymphocyte-predominant Hodgkin's disease.

28 OS in pediatric patients with advanced-stage Hodgkin's disease.

29 taneous T-cell lymphomas, and 5/38 classical Hodgkin's disease.

30 and autografting in the sustained control of Hodgkin's disease.

31 ells occur in nodular lymphocyte-predominant Hodgkin's disease.

32 5 years, and 12.2 years, respectively, after Hodgkin's disease.

33 developed multiple myeloma 16.5 years after Hodgkin's disease.

34 ted a 41% complete response in patients with Hodgkin's disease.

35 ased CD30+ lymphoproliferative disorders and Hodgkin's disease.

36 me patients with Epstein-Barr virus-positive Hodgkin's disease.

37 aining for CD95 was seen in 9 of 10 cases of Hodgkin's disease.

38 7 B- and 5 T-cell lymphomas, and 10 cases of Hodgkin's disease.

39 tment, age at treatment, sex, and time after Hodgkin's disease.

40 ho were treated with radiation for childhood Hodgkin's disease.

41 factor superfamily and a surface marker for Hodgkin's disease.

42 possible localization of primary extra nodal Hodgkin's disease.

43 ts who had prior mediastinal irradiation for Hodgkin's disease.

44 lymphomas and approximately 40% of cases of Hodgkin's disease.

45 c patients with unfavorable presentations of Hodgkin's disease.

46 been identified as effective treatments for Hodgkin's disease.

47 eive newer, combined modality treatments for Hodgkin's disease.

48 e standard regimen for treatment of advanced Hodgkin's disease.

49 xistence of chronic lymphocytic leukemia and Hodgkin's disease.

50 MOPP/ABV hybrid are effective therapies for Hodgkin's disease.

51 relapse after combined-modality therapy for Hodgkin's disease.

52 d with at least 35 Gy to the mediastinum for Hodgkin's disease.

53 d these regimens as initial chemotherapy for Hodgkin's disease.

54 ked in the first 5 years, predominantly from Hodgkin's disease.

55 monoclonal antibody (mAb)-based therapies of Hodgkin's disease.

56 an association between cigarette smoking and Hodgkin's disease.

57 er were treated for clinical stage IA to IIB Hodgkin's disease.

58 APEC-B in patients with previously untreated Hodgkin's disease.

59 or II) disease or advanced (stage III or IV) Hodgkin's disease.

60 is an important preventable risk factor for Hodgkin's disease.

61 -term follow-up care in patients treated for Hodgkin's disease.

62 ctal cancer (10.8, 1.3-38.8; two cases), and Hodgkin's disease (11.4, 1.4-41.3; two cases).

63 ter steroid treatment (T5) in 40 patients (7 Hodgkin's Disease, 13 Acute Myeloblastic Leukemia, 5 Acu

64 s reacted with the BSAP antisera, whereas in Hodgkin's disease, 2 of 4 (50%) nodular lymphocytic pred

65 ll neoplasms, nodular lymphocyte-predominant Hodgkin's disease (7 cases), CD4+ cutaneous T-cell lymph

66 n KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold), multiple myeloma (4.5-fold

67 ific deaths at 25 years were 9.8%+/-1.6% for Hodgkin's disease, 8.1%+/-2.6% for second malignancy, 4.

68 n of a child who had completed treatment for Hodgkin's disease, a PET study strongly suggested recurr

69 st were those for lung cancer, leukemia, and Hodgkin's disease (all 99.9%).

70 e median age at diagnosis was 24.6 years for Hodgkin's disease and 42.6 years for breast cancer.

71 of the EBV-positive, GC-associated lymphomas Hodgkin's disease and Burkitt's lymphoma.

72 lated CD30+ forms of lymphoma, such as CD30+ Hodgkin's disease and CD30+ cutaneous T-cell lymphoma.

73 The autopsy confirmed the existence of Hodgkin's disease and chronic lymphocytic leukemia.

74 asis to understand the genes responsible for Hodgkin's disease and develop novel diagnostic markers a

75 nfect on and suggests an association between Hodgkin's disease and HIV-1 infection.

76 in splenectomized patients in remission from Hodgkin's disease and in healthy Afro-Caribbean subjects

77 Patients with CD30+ tumors (Hodgkin's disease and Ki-1+ non-Hodgkin's lymphoma) freq

78 All other tumors, including Hodgkin's disease and lymphomatoid papulosis, were ALK1-

79 le association between radiation therapy for Hodgkin's disease and mesothelioma.

80 roved useful in the staging and follow-up of Hodgkin's disease and non-Hodgkin's lymphoma (especially

81 ), and may be helpful to distinguish between Hodgkin's disease and non-Hodgkin's lymphoma in difficul

82 There was one death from Hodgkin's disease and one death from an M5 acute leukemi

83 ular adverse effect of radiation exposure in Hodgkin's disease and other types of cancer manifesting

84 on library with TrAb sera from patients with Hodgkin's disease and paraneoplastic cerebellar degenera

85 ly untreated stages III2A, IIIB, IVA, or IVB Hodgkin's disease and patients in first relapse after ra

86 d of therapy is rarely seen in patients with Hodgkin's disease and should be considered a manifestati

87 erature on breast cancer after treatment for Hodgkin's disease and show that high risk is particularl

88 ole of radiotherapy and high-dose therapy in Hodgkin's disease and the non-Hodgkin's lymphomas.

89 s expressed by vascular endothelial cells in Hodgkin's disease and various solid tumors in mice and h

90 otomy could be safely avoided in early-stage Hodgkin's disease and whether chemotherapy should be a p

91 durable responses in melanoma, renal cancer, Hodgkin's diseases and lung cancer.

92 isorders, including posttransplant lymphoma, Hodgkin's disease, and Burkitt's lymphoma, as well as na

93 e expression in nasopharyngeal carcinoma and Hodgkin's disease, and differs from the full spectrum of

94 ers, such as nasopharyngeal carcinoma (NPC), Hodgkin's disease, and gastric carcinoma.

95 of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virologic

96 Hodgkin's disease, and lymphomatoid papulosis, and to es

97 stic leukemia, chronic myelogenous leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma.

98 the management of early stage breast cancer, Hodgkin's disease, and to a lesser extent other thoracic

99 erse non-Hodgkin's lymphomas overexpress the Hodgkin's disease antigen CD30 (CD30(hi)), a tumor necro

100 cell lymphomas and leukemias and variants of Hodgkin's disease are collected and defined.

101 Unusual types of NHL and manifestations of Hodgkin's disease are seen in HIV-infected individuals a

102 , B-lineage leukemias, multiple myeloma, and Hodgkin's disease, as well as certain carcinomas.

103 rrent disease were alive without evidence of Hodgkin's disease at the time of last follow-up.

104 berg cells in nodular lymphocyte-predominant Hodgkin's disease, belong to the B-cell lineage.

105 negative cases, including three NHL and four Hodgkin's disease biopsy samples.

106 age, diagnosis of non-Hodgkin's lymphoma or Hodgkin's disease, bone marrow involvement, prior radiat

107 e marrow transplant (BMT) can cure recurrent Hodgkin's disease, but more than half of patients will p

108 the number of genes known to be expressed in Hodgkin's disease by 20-fold to 2,666 named genes.

109 tric patients with stages I and II favorable Hodgkin's disease can be cured with limited therapy that

110 Pediatric patients with low-risk Hodgkin's disease can be cured with therapy without an a

111 Finally, eleven of the Hodgkin's disease cases were also subjected to Southern

112 All of the Hodgkin's disease cases, eight of the large-cell lymphom

113 caspase-3 is commonly expressed in classical Hodgkin's disease (CHD); however, the biological signifi

114 ighty-two patients with previously untreated Hodgkin's disease, clinical stages I/II (plus mediastina

115 ogeneity and paucity of "malignant" cells in Hodgkin's disease continue to limit our ability to artic

116 Therapy for Hodgkin's disease continues to evolve toward the most ef

117 IV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into

118 Cultured Hodgkin's disease-derived (HD) cell lines, however, were

119 ker for Reed-Sternberg cells and variants of Hodgkin's disease (except L&H types), and may be helpful

120 demonstrated that patients with early-stage Hodgkin's disease experience a short-term decrease in QO

121 29 B and 2 T cell lymphomas, and 9 cases of Hodgkin's disease expressed CD95.

122 nal diagnosis of bone tumor, brain tumor, or Hodgkin's disease; female sex; and an income less than $

123 The malignant Reed-Sternberg cell of Hodgkin's disease, first described a century ago, has re

124 Additionally, 17 cases of Hodgkin's disease fixed in B5 and formalin were compared

125 ve palliation with low toxicity in recurrent Hodgkin's disease following transplant.

126 fective treatment strategy for patients with Hodgkin's disease for whom induction chemotherapy fails.

127 , whereas patients with multiple myeloma and Hodgkin's disease had worse outcomes as a result of high

128 The successful treatment of Hodgkin's disease has been associated with an increased

129 ticular, extended follow-up of patients with Hodgkin's disease has revealed an increased risk of brea

130 sfully treated children and adolescents with Hodgkin's disease have a substantial risk for the occurr

131 Patients treated for early-stage Hodgkin's disease have a sustained excess mortality risk

132 -AIDS-defining cancers, germ cell tumors and Hodgkin's disease, have been reported in the setting of

133 rative disorders (PTLD); however, reports of Hodgkin's disease (HD) after transplantation are rare.

134 n expression was also studied in 51 cases of Hodgkin's disease (HD) and 17 large B-cell lymphomas (LB

135 carcinoma, from infectious mononucleosis to Hodgkin's disease (HD) and Burkitt's lymphoma.

136 large-cell lymphomas (DLCL) and 128 cases of Hodgkin's disease (HD) and discusses the clinical featur

137 homa (BL), post-transplant B cell lymphomas, Hodgkin's disease (HD) and nasopharyngeal carcinoma (NPC

138 y (HDT) with autologous stem cell rescue for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL)

139 Accurate staging of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL)

140 patients with a history of presumably cured Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

141 as documented survival benefits for relapsed Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

142 carboxy (C)-terminal mutations occurring in Hodgkin's disease (HD) and reactive tissues from two dif

143 men who are exposed to chest irradiation for Hodgkin's disease (HD) are at increased risk of breast c

144 Approximately 40% of Hodgkin's disease (HD) cases in Western countries carry

145 ts Study Group cohort of 1,380 children with Hodgkin's disease (HD) diagnosed between 1955 and 1986 i

146 Epstein Barr virus (EBV)+ Hodgkin's disease (HD) expresses clearly identified tumo

147 m 190 patients with histologically confirmed Hodgkin's disease (HD) for the presence of Epstein-Barr

148 the Hodgkin's Reed-Sternberg (H-RS) cells in Hodgkin's disease (HD) had the greatest abundance of hsp

149 The treatment of early-stage Hodgkin's disease (HD) has evolved from radiotherapy alo

150 non-Hodgkin's lymphoma (NHL) in 48 patients, Hodgkin's disease (HD) in 14 patients, other neoplastic

151 sted to have an impact on the development of Hodgkin's disease (HD) in women.

152 Hodgkin's disease (HD) is a lymphoid malignancy characte

153 Hodgkin's disease (HD) is a lymphoma characterized by a

154 Hodgkin's disease (HD) is a malignancy that displays a b

155 Hodgkin's disease (HD) is an example of a malignancy whi

156 lymphoma with the characteristic features of Hodgkin's disease (HD) occasionally develops in patients

157 A subset of Hodgkin's disease (HD) patients have detectable Epstein-

158 Thirty-nine previously treated Hodgkin's disease (HD) patients were immunized with 7-va

159 ineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy follow

160 mphoma (ALCL) and the Reed-Sternberg cell of Hodgkin's disease (HD) remains largely uncertain.

161 Refinement in managing pediatric Hodgkin's disease (HD) requires understanding of factors

162 Cardiovascular status was assessed in 48 Hodgkin's disease (HD) survivors at a median of 14.3 yea

163 and risk factors for stroke among childhood Hodgkin's disease (HD) survivors.

164 in patients with lymphocyte-predominant (LP) Hodgkin's disease (HD) to determine whether these patien

165 CL), other non-Hodgkin's lymphomas (NHL), or Hodgkin's disease (HD) were eligible if their cancer was

166 ield radiotherapy in patients with favorable Hodgkin's disease (HD) who have been laparotomy-staged.

167 heral T cell, 13 with low-grade NHL, 31 with Hodgkin's disease (HD), and 6 with lymphomatoid papulosi

168 nasopharyngeal carcinoma (NPC), a subset of Hodgkin's disease (HD), and in EBV-associated lymphoprol

169 six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B

170 ted tumors such as nasopharyngeal carcinoma, Hodgkin's disease (HD), and T/NK lymphomas.

171 and Reed-Sternberg (HRS) cells of classical Hodgkin's disease (HD), but its clinical significance re

172 mortality after the successful treatment of Hodgkin's disease (HD), little is known about the molecu

173 dian, 40) with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), multiple myeloma (MM), or acute

174 n 1982 and 1995 were included in this study: Hodgkin's disease (HD), n = 12; intermediate/high-grade

175 -424 of EBNA-4 in 25 cases of EBV-associated Hodgkin's disease (HD), nine cases of AIDS-related non-H

176 Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD).

177 Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD).

178 diopulmonary protectant during treatment for Hodgkin's disease (HD).

179 y on the potential for fertility of men with Hodgkin's disease (HD).

180 st cancer, non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD).

181 T cells in patients who had been treated for Hodgkin's disease (HD).

182 he immunohistochemical detection of LMP2A in Hodgkin's disease (HD).

183 -Barr virus (EBV) is etiologically linked to Hodgkin's disease (HD).

184 Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD).

185 hly expressed on the Reed Sternberg cells of Hodgkin's disease (HD).

186 h aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).

187 with diffuse large B-cell lymphoma (n = 12), Hodgkin's disease (HD; n = 12), multiple myeloma (n = 2)

188 y disease is effective in bulky and advanced Hodgkin's disease in a multi-institutional setting.

189 s of this study show that, in advanced-stage Hodgkin's disease in children, equivalent results can be

190 mbination chemotherapy regimens for advanced Hodgkin's disease in pediatric patients.

191 o cure acute childhood leukemia and advanced Hodgkin's disease in the 1960s and early 1970s overcame

192 The management of early-stage Hodgkin's disease in the United States is controversial.

193 rd therapy for children and adolescents with Hodgkin's disease includes combination chemotherapy and

194 Relapse of Hodgkin's disease increased the risk of second malignanc

195 ednisone (NOVP) combination chemotherapy for Hodgkin's disease increases the frequencies of the speci

196 ar lymphomas, 3 mantle cell lymphomas, and 2 Hodgkin's disease) involving GIT.

197 tra nodal and extra lymphatic propagation of Hodgkin's disease is a characteristic of the fourth stag

198 Hodgkin's disease is a common malignancy of the lymphoid

199 alone in selected patients with early-stage Hodgkin's disease is associated with disease control rat

200 urate disease status in patients treated for Hodgkin's disease is discussed, along with recommendatio

201 tion for patients with early-stage/favorable Hodgkin's disease is highly effective and without demons

202 Although Hodgkin's disease is highly responsive to treatments tha

203 major consequence of successful treatment of Hodgkin's disease is the development of second malignant

204 biological significance of its expression in Hodgkin's disease is unknown.

205 ong the highest reported in association with Hodgkin's disease, is unusual.

206 ransplant-related mortality rates decline in Hodgkin's disease, it is predicted that cure rates and l

207 Exclusion of deaths due to Hodgkin's disease led to small changes in the estimates

208 We found that in fresh Hodgkin's disease lymph node biopsies, a subset of HRS c

209 elated cancers, elevated SIRs were found for Hodgkin's disease (male, 8.0; female, 6.4; heterosexuall

210 lso present in the cytoplasmic domain of the Hodgkin's disease marker, CD30, and binds TRAF3 in vitro

211 C promoter or Cp) in Burkitt's lymphoma and Hodgkin's disease may play an important role in the path

212 However, Hodgkin's disease may produce several inhibitory effects

213 ts, alternative malignancies were diagnosed (Hodgkin's disease; metastatic neuroendocrine carcinoma;

214 ectal cancer incidence and mortality, and of Hodgkin's disease mortality were increased.

215 S leads to a significantly increased risk of Hodgkin's disease, multiple myeloma, brain cancer, and s

216 of follow-up, 71 fatal events resulted from Hodgkin's disease (n=36), second malignancies (n=14), in

217 nfection including posttransplant lymphomas, Hodgkin's disease, nasopharyngeal carcinoma, and AIDS-re

218 methylated and silent in Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and nasal l

219 and B strains contrasts with EBV-associated Hodgkin's disease, nasopharyngeal carcinoma, and post-tr

220 apy and low-dose radiotherapy in early stage Hodgkin's disease need our attention in rigorously desig

221 d be generated ex vivo from 13 patients with Hodgkin's disease: nine with active relapsed disease and

222 clonality of nodular lymphocyte-predominant Hodgkin's disease (NLPHD) and the relationship to compos

223 Nodular lymphocyte predominance Hodgkin's disease (NLPHD) is characterized by the presen

224 caspase-3 in nodular lymphocyte predominance Hodgkin's disease (NLPHD) was evaluated by immunohistoch

225 reticulum cell, for the neoplastic cells of Hodgkin's disease, notably in nodular sclerosis type.

226 and histology other than nodular sclerosing Hodgkin's disease (NSHD).

227 's transformation occurred in 9 patients and Hodgkin's disease occurred in 4 patients.

228 mokers had a significantly increased risk of Hodgkin's disease (odds ratio (OR) = 1.8, 95% confidence

229 Primary extra nodal Hodgkin's disease of bone is manifested with painful swe

230 chronic lymphocytic leukemia (one patient), Hodgkin's disease (one patient), and adult T-cell leukem

231 of cholestasis, but not pruritus of uremia, Hodgkin's disease, or atopic dermatitis.

232 Certain types of cancer (Hodgkin's disease, osteosarcoma/Ewing's sarcoma, rhabdom

233 contrast, Burkitt's lymphoma (P=0.0047) and Hodgkin's disease (P=0.016) were only observed in late P

234 healthy men and to repeated samples of eight Hodgkin's disease patients before treatment, 35-50 days

235 tumors in pathologically staged and treated Hodgkin's disease patients followed for long intervals t

236 52 patients, compared with three (4%) of 68 Hodgkin's disease patients in a comparison cohort who di

237 nd Marrow Transplant Registry (ABMTR) on 122 Hodgkin's disease patients who failed to achieve complet

238 Hodgkin's disease patients who never achieve complete re

239 whole saliva flow rates were measured in 11 Hodgkin's disease patients who received therapeutic dose

240 re reported only for NHL patients, excluding Hodgkin's disease patients.

241 59 children and adolescents with unfavorable Hodgkin's disease received three alternating cycles (tot

242 Sixty patients with Hodgkin's disease, refractory to or at first recurrence

243 gents in the etiology of solid cancers after Hodgkin's disease require detailed investigation.

244 Survivors of pediatric Hodgkin's disease require lifelong evaluation and cancer

245 lymphoma and nodular lymphocyte predominance Hodgkin's disease, respectively).

246 mortality from all causes, causes other than Hodgkin's disease, second tumors, and cardiac disease re

247 er (PTLD; SIR = 54.3; 95% CI, 39.5 to 41.1), Hodgkin's disease (SIR = 14.8; 95% CI, 3.9 to 32.9), or

248 Hodgkin's disease (SIR = 2.5; 95% CI 1.5-3.9), and anal

249 motherapy regimen plus radiotherapy to bulky Hodgkin's disease sites.

250 es in non-AIDS-defining malignancies such as Hodgkin's disease, skin, lung, anal, and kidney cancers

251 n a randomized clinical trial in early-stage Hodgkin's disease (Southwest Oncology Group [SWOG] 9133)

252 Hodgkin's disease stage, patient age, splenectomy, and t

253 elangiectasia (AT) gene, ATM, in a cohort of Hodgkin's disease survivors with secondary malignancies.

254 neoplasms were observed in this cohort of 52 Hodgkin's disease survivors, with 18 patients (35%) deve

255 opment of secondary neoplasms in a subset of Hodgkin's disease survivors.

256 is an effective treatment for all stages of Hodgkin's disease that present with a large mediastinal

257 In 50% of patients with Hodgkin's disease, the tumor cells are EBV antigen-posit

258 Aggressive Hodgkin's disease therapy is successful, but patients ha

259 active in both nasopharyngeal carcinoma and Hodgkin's disease tissues.

260 blastoid cell lines and are also detected in Hodgkin's disease tissues.

261 creening of patients who have recovered from Hodgkin's disease to aid early diagnosis and ensure the

262 roup followed a cohort of 1380 children with Hodgkin's disease to determine the incidence of second n

263 neck and chest are obtained at diagnosis of Hodgkin's disease to establish disease extent, plan radi

264 his may be useful in assigning children with Hodgkin's disease to risk-adapted therapy.

265 Most patients who present with Hodgkin's disease today can be cured of their disease.

266 A striking finding was observed for cases of Hodgkin's disease (total 187 cases).

267 A cohort of 5,519 British patients with Hodgkin's disease treated during 1963 through 1993 was a

268 ns in children and adolescents with low-risk Hodgkin's disease treated with vinblastine, doxorubicin,

269 s enrolled onto two Pediatric Oncology Group Hodgkin's disease treatment protocols.

270 ith lymphomatoid papulosis (fourteen cases), Hodgkin's disease (twelve cases), and CD30+ large-cell l

271 ren), Kaposi's sarcoma (KS; three children), Hodgkin's disease (two children), vaginal carcinoma in s

272 and in the FRC and endothelium of classical Hodgkin's disease, two tumor types that also showed an a

273 ith diagnosed relapsed or primary refractory Hodgkin's disease underwent this treatment.

274 fects for smoking in relation to the risk of Hodgkin's disease using data from the Selected Cancers S

275 lative risk for invasive breast cancer after Hodgkin's disease was 4.7 (95% confidence interval, 3.4

276 ond neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence

277 it was observed that successful treatment of Hodgkin's disease was associated with risk of a second m

278 ldren and adolescents with stages III and IV Hodgkin's disease was conducted by the Children's Cancer

279 The risk for developing breast cancer after Hodgkin's disease was greatest in women who were under t

280 ne cases of breast cancer in 65 survivors of Hodgkin's disease were analyzed.

281 odular sclerosing and lymphocyte predominant Hodgkin's disease were derived from an unusual B-cell li

282 age (PS) IA to IIA or clinical stage (CS) IA Hodgkin's disease were entered onto a single-arm prospec

283 escents with stages IIB, IIIA2, IIIB, and IV Hodgkin's disease were randomized to receive eight cycle

284 clinical stage IA to IIA supradiaphragmatic Hodgkin's disease were randomized without staging laparo

285 Adult patients (N = 856) with advanced Hodgkin's disease were randomly assigned to treatment wi

286 0 and April 1993, 56 pediatric patients with Hodgkin's disease were treated on a single-arm trial at

287 diatric patients with clinical stage I to IV Hodgkin's disease were treated with chemotherapy and low

288 inical stages I and II, favorable (nonbulky) Hodgkin's disease were treated with four cycles of VAMP

289 One hundred ten children with low-risk Hodgkin's disease were treated with four cycles of VAMP

290 patients with laparotomy staged (PS) IA-IIIB Hodgkin's disease were treated with radiation therapy (R

291 like B-cell chronic lymphocytic leukemia and Hodgkin's disease, where IL-13 modulates apoptosis or tu

292 m patients with nasopharyngeal carcinoma and Hodgkin's disease, where LMP1 is also found.

293 Patients with Hodgkin's disease, which is either refractory or recurs

294 lants should be considered for patients with Hodgkin's disease who do not achieve complete remission

295 We analyzed retrospectively 81 patients with Hodgkin's disease who had serial [(18)F]FDG-PET scans pe

296 acial zygomycosis in a 24-year-old male with Hodgkin's disease who underwent chemotherapy and autolog

297 control populations, survivors of pediatric Hodgkin's disease who were treated before 1990 face an i

298 secutive, previously untreated patients with Hodgkin's disease who were younger than 20 years of age

299 ms focus on obtaining a relapse-free cure of Hodgkin's disease with judicious use of radiation and al

300 = cisplatinum), in a group of patients with Hodgkin's disease with such poor risk characteristics.